alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS IN THE QUARTERLY REPORT ON FORM 10-Q OF DIGITAL MICROWAVE
CORPORATION FOR THE QUARTER ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             APR-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                          31,259
<SECURITIES>                                    15,114
<RECEIVABLES>                                   65,462
<ALLOWANCES>                                     3,836
<INVENTORY>                                     57,668
<CURRENT-ASSETS>                               169,204
<PP&E>                                          55,955
<DEPRECIATION>                                  33,744
<TOTAL-ASSETS>                                 208,691
<CURRENT-LIABILITIES>                           52,609
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           372
<OTHER-SE>                                     155,025
<TOTAL-LIABILITY-AND-EQUITY>                   208,691
<SALES>                                         64,558
<TOTAL-REVENUES>                                64,558
<CGS>                                           41,346
<TOTAL-COSTS>                                   41,346
<OTHER-EXPENSES>                                17,206
<LOSS-PROVISION>                                   402
<INTEREST-EXPENSE>                                 203
<INCOME-PRETAX>                                  6,492
<INCOME-TAX>                                       682
<INCOME-CONTINUING>                              5,810
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     5,810
<EPS-PRIMARY>                                      .14
<EPS-DILUTED>                                      .13
        

</TABLE>
Exhibit 99.14

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                 SECTIION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tonga Capital Corp (the "Company") on
Form 10-QSB for the period ending June 30, 2004 as filed with the Securities and
Exchange Commission on the date hereof (the "Report").  I , Jeffrey Ploen, Chief
Executive Officer of the Company,  certify,  pursuant to 18 USC 1350, as adopted
pursuant  to 906 of the  Sarbancs-Oxley  Act of  2002,  that  to the  best of my
knowledge and belief.

     (1)  The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934: and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.



                                     /s/ Jeffrey Ploen
                                     Jeffrey Ploen, Chief Executive Officer &
                                                   Chief Financial Officer

Dated: August 13, 2004
§ 207.81 What registration and listing information will FDA make available for public disclosure? ( a ) Except as provided in paragraphs (b) and (c) of this section, the following information will be available for public disclosure, upon request or at FDA's discretion: ( 1 ) All establishment registration information, and
( 2 ) After a drug is marketed, information obtained under § 207.33, § 207.49, § 207.53, § 207.54, or § 207.57.
( b ) Unless such information is publicly available or FDA finds that confidentiality would be inconsistent with protection of the public health, FDA will not make publicly available: ( 1 ) Any information submitted under § 207.55 as the basis upon which it has been determined that a particular drug is not subject to section 505 or 512 of the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act,
( 2 ) The names of any inactive ingredients submitted under § 207.49(a)(4) for which the registrant makes a valid assertion of confidentiality under § 20.61 of this chapter or other provision of law, or
( 3 ) Drug listing information obtained under § 207.33(d)(3), § 207.49(a)(9) and (12), § 207.53(b) and (c), or § 207.54(a) or (c).
( c ) FDA may determine, in limited circumstances and on a case-by-case basis, that it would be consistent with the protection of the public health and the Freedom of Information Act to exempt from public disclosure specific information identified in paragraph (a) of this section.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1588 Pectins. ( a ) The pectins (CAS Reg. No. 9000-69-5) are a group of complex, high molecular weight polysaccharides found in plants and composed chiefly of partially methylated polygalacturonic acid units. Portions of the carboxly group occur as methyl esters, and the remaining carboxyl groups exist in the form of the free acid or as its ammonium, potassium, or sodium (CAS Reg. No. 9000-59-8) salts, and in some types as the acid amide. Thus, the pectins regulated in this section are the high-ester pectins, low-ester pectins, amidated pectins, pectinic acids, and pectinates. Pectin is produced commercially by extracting citrus peel, apple pomace, or beet pulp with hot dilute acid (pH 1.0 to 3.5, 70° to 90 °C). The extract is filtered, and pectin is then precipitated from the clear extract with ethanol or isopropanol, or as the copper or aluminum salt. The acid extract is sometimes spray- or roller-dried, or it is concentrated to be sold as liquid pectin.
( b ) The ingredients meet the specifications of the Food Chemical Codex, 3d Ed. (1981), p. 215, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredients are used in food with no limitation other than current good manufacturing practice. The affirmation of these ingredients as generally recognized as safe (GRAS) as direct human food ingredients is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredients are used as emulsifiers as defined in § 170.3(o)(8) of this chapter and as stabilizers and thickeners as defined in § 170.3(o)(28) of this chapter.
( 2 ) The ingredients are used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for these ingredients different from the uses established in this section do not exist or have been waived.
[48 FR 51149, Nov. 7, 1983]
EXHIBIT 11

                          STATEMENT RE COMPUTATION OF
                              PER SHARE EARNINGS

Primary earnings per common share are computed by dividing net income by the
weighted average number of common shares outstanding and common equivalent
shares with a dilutive effect. Common equivalent shares are shares which may
be issuable upon exercise of outstanding stock options and warrants. Stock
options and warrants were included in earnings per primary common share
computations for 1995 and 1994.

Fully diluted earnings per common share are determined on the assumption that
the weighted average number of common shares and common equivalent shares
outstanding is further increased by the effect of the end of period market
price on stock options and stock warrants. Stock options and stock warrants
were included in earnings per fully diluted common share computations for 1995
and 1994.

The following table presents information necessary for the computation of
earnings per share, on both primary and fully diluted basis, for the three and
nine months ended September 30, 1995 and 1994.
<TABLE>
<CAPTION>
                                                Three Months Ended             Nine Months Ended
                                                     Sept. 30,                     Sept. 30,
                                             -------------------------     -------------------------
                                                1995           1994           1995           1994
                                             ----------     ----------     ----------     ----------
<S>                                          <C>            <C>            <C>            <C>       
Average number of
common shares
outstanding ............................     14,970,569     15,314,569     14,985,870     15,226,965

Common share equivalents
on stock options and stock
warrants based on average
market price ...........................        453,283        487,295        444,951        524,415
                                             ----------     ----------     ----------     ----------
Average number of common
shares outstanding to compute
primary earnings per share .............     15,423,852     15,801,864     15,430,821     15,751,380

Incremental common share
equivalent on stock options
and stock warrants based on
end of period market price .............         31,087             --         14,014          1,538
                                             ----------     ----------     ----------     ----------
Average number of common
shares outstanding to compute
fully diluted earnings per share .......     15,454,939     15,801,864     15,444,835     15,752,918
                                             ==========     ==========     ==========     ==========
</TABLE>



                                      23
H. Res. 541

In the House of Representatives, U.S., 

April 5, 2006.

Whereas on October 10, 2005, the Royal Swedish Academy 

of Sciences awarded the Nobel Prize in Physics for 2005 

to Drs. Roy J. Glauber, John L. Hall, and Theodor W. 

Ha ̈nsch for their pioneering discoveries in the field of optics; 

Whereas their contributions to the quantum theory of optical 

coherence and development of laser-based precision spectroscopy, including the optical frequency comb technique, 

has led to improvements in the accuracy of precision instruments such as GPS locators, atomic clocks, and navigation systems; 

Whereas John L. Hall recently retired from a long career 

with the National Institute of Standards and Technology 

(NIST), Quantum Physics Division, and was one of the 

founding fellows of the JILA, a joint Federal lab/university cooperative effort supporting research and post-graduate training; 

Whereas the NIST, founded in 1901, and its laboratories and 

collaborations with academia have contributed to the 

achievements of present and past Nobel Prize winners by 

supporting research that strengthens the global economic 

competitiveness of the United States through the develop-
2

•HRES 541 EH 

ment of technologies, measurement methods, and standards; 

Whereas John L. Hall is one of three NIST researchers to 

have received a Nobel Prize; 

Whereas on October 10, 2005, the Royal Swedish Academy 

of Sciences awarded the Nobel Prize in Chemistry for 

2005 to Drs. Yves Chauvin, Robert H. Grubbs, and Richard R. Schrock for their pioneering discoveries in the 

field of organic chemistry; 

Whereas their research on metathesis reactions and the development of the metathesis method in organic synthesis 

has resulted in a major advance for ‘‘green chemistry’’ 

and the development of pharmaceuticals that can be 

made through methods that are more efficient and generate fewer hazardous wastes: Now, therefore, be it

Resolved, That the House of Representatives—

(1) recognizes and honors Drs. Roy J. Glauber, 

John L. Hall, and Theodor W. Ha ̈nsch; 

(2) recognizes and honors Drs. Yves Chauvin, Robert H. Grubbs, and Richard R. Schrock; and 

(3) acknowledges the importance of National Institute of Standards and Technology research and its contributions to United States industry, academia, and government.

Attest: 

Clerk.
EXHIBIT 32

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CirTran Corporation on Form 10-QSB
for the period ending June 30, 2005, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), Iehab Hawatmeh, President and
Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

(1)  The Report fully complies with the  requirements  of section 13(a) or 15(d)
     of the Securities Exchange Act of 1934; and

(2)  The information  contained in the Report fairly  presents,  in all material
     respects, the financial condition and result of operations of the Company.

August 12, 2005
                             /s/ Iehab Hawatmeh
                           ------------------------------------------
                           Iehab J. Hawatmeh
                           President and Chief Financial Officer
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 01-20734 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus KENNETH AYERS, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Southern District of Texas USDC No. H-01-CR-82-1

-------------------- April 11, 2002 Before SMITH, DeMOSS, and PARKER, Circuit Judges. PER CURIAM: * Kenneth Ayers appeals his guilty-plea conviction for possession with the intent to distribute methamphetamine in violation of 21 U.S.C. § 841(a)(1) and § 841(b)(1)(C). He argues that under Apprendi v. New Jersey , 530 U.S. 466 (2000), 21 U.S.C. § 841 is facially unconstitutional; however, he concedes that this court rejected an Apprendi -based challenge to the constitutionality of § 841 in United States v. Slaughter , 238 F.3d 580, 581-82 (5th Cir. 2000), cert. denied , 121 S. Ct. 2015 (2001). He asserts that he is raising the issue to preserve itNo. 01-20734 -2- for en banc or Supreme Court review. He did not raise the issue in the district court.
In Slaughter , 238 F.3d at 582, we held that there is "nothing in the Supreme Court decision in Apprendi which would permit [this court] to conclude that 21 U.S.C. § 841(a) and (b) ... are unconstitutional on their face." A panel of this court cannot overrule a prior panel’s decision in the absence of an intervening contrary or superseding decision by this court sitting en banc or by the United States Supreme Court. Burge v. Parish of St. Tammany , 187 F.3d 452, 466 (5th Cir. 1999). Moreover, the Ninth Circuit has reversed its decision in United States v. Buckland , 259 F.3d 1157, 1160-68 (9th Cir. 2001), rev’d en banc , 277 F.3d 1173 (9th Cir. 2002), the only circuit-level decision that supported Ayers’s argument. AFFIRMED.
##### 



EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER

Pursuant to

Section 906 of the Sarbanes-Oxley Act of
2002


I, Keith A. Meister, President and Chief
Executive Officer (Principal Executive Officer) of American
Property Investors, Inc., the General Partner of American Real
Estate Partners, L.P. (the Registrant), certify that
to the best of my knowledge, based upon a review of the American
Real Estate Partners, L.P., quarterly report on Form 10-Q
for the period ended September 30, 2004 of the Registrant
(the Report):



| |                                                                                                                                                                    
| | -------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | (1) The Report fully complies with the
    requirements of Section 13(a) or 15(d) of the Securities
    Exchange Act of 1934, as amended; and                      
|
| | (2) The information contained in the Report
    fairly presents, in all material respects, the financial
    condition and results of operations of the Registrant.



| |                     
| | --------------------
| | /s/ KEITH A. MEISTER
| |                     



| |                                             
| | --------------------------------------------
| | Keith A. Meister                            
| | President and Chief Executive Officer
    of
| | American Property Investors, Inc.,          
| | the General Partner of                      
| | American Real Estate Partners, L.P.         

Date: November 9, 2004
§ 500.26 Timed-release dosage form drugs. ( a ) Drugs are being offered in dosage forms that are designed to release the active ingredients over a prolonged period of time. There is a possibility of unsafe overdosage or ineffective dosage if such products are improperly made and the active ingredients are released at one time, over too short or too long a period of time, or not released at all. Drugs marketed in this form, which are referred to by such terms as timed-release, controlled-release, prolonged-release, sustained-release, or delayed-release drugs, are regarded as new animal drugs within the meaning of section 201(v) of the Federal Food, Drug, and Cosmetic Act.
( b ) Timed-release dosage form animal drugs that are introduced into interstate commerce are deemed to be adulterated within the meaning of section 501(a)(5) of the act and subject to regulatory action, unless such animal drug is the subject of an approved new animal drug application, or listed in the index, as required by paragraph (a) of this section.
( c ) The fact that the labeling of this kind of drug may claim delayed, prolonged, controlled, or sustained-release of all or only some of the active ingredients does not affect the new animal drug status of such articles. A new animal drug application or index listing is required in any such case.
( d ) New animal drug applications for timed-release dosage form animal drugs must contain, among other things, data to demonstrate safety and effectiveness by establishing that the article is manufactured using procedures and controls to ensure release of the total dosage at a safe and effective rate. Data submitted in the new animal drug application must demonstrate that the formulation of the drug and the procedures used in its manufacture will ensure release of the active ingredient(s) of the drug at a safe and effective rate and that these release characteristics will be maintained until the expiration date of the drug. When the drug is intended for use in food-producing animals, data submitted must also demonstrate that, with respect to possible residues of the drug, food derived from treated animals is safe for consumption.
[42 FR 8635, Feb. 11, 1977, as amended at 60 FR 38480, July 27, 1995; 72 FR 69120, Dec. 6, 2007]
Fw: SENT TO OMB - OAR final action SAN 5163: Review of the Primary 

National Ambient Air Quality Standards for Sulfur Dioxide

Mary Henigin to:

Michael Stewart, Lydia Wegman, Rosalina 

Rodriguez, Karen Martin, Tricia Crabtree, Ron 

Evans, Kathy Kaufman

05/04/2010 03:43 PM

Cc: Peter South, Jan Cortelyou-Lee

----- Forwarded by Mary Henigin/DC/USEPA/US on 05/04/2010 03:41 PM -----

From: Nathaniel Jutras/DC/USEPA/US

To: Nicole Owens/DC/USEPA/US@EPA, Eileen Pritchard/DC/USEPA/US@EPA, Joseph-J 

Dougherty/DC/USEPA/US@EPA, Mary Henigin/DC/USEPA/US@EPA, Alan 

Rush/DC/USEPA/US@EPA, Mariana Cubeddu/DC/USEPA/US

Cc: Venu Ghanta/DC/USEPA/US@EPA, Alexander Cristofaro/DC/USEPA/US@EPA, Lisa 

Heinzerling/DC/USEPA/US@EPA, Robin Kime/DC/USEPA/US@EPA

Date: 05/04/2010 03:38 PM

Subject: SENT TO OMB - OAR final action SAN 5163: Review of the Primary National Ambient Air Quality 

Standards for Sulfur Dioxide

Today 5/4/2010, final action SAN 5163: Review of the Primary National Ambient Air Quality Standards for Sulfur 

Dioxide was sent to OMB.

This Tier 1 action has been updated in RAPIDS. 

Thank you,

Nathaniel P. Jutras

U.S. Environmental Protection Agency

OA / OPEI/ Regulatory Management Division

Washington, DC 20406

(P) (202) 564.0301 (F) (202) 564.0965
38876.

#### MORRIS v. HORTON *et al.*

Decided June 12, 1961.

Felton, Chief Judge.

Exceptions to excerpts from the charge of the trial court in the special grounds of a motion for a new trial, which require the consideration of the evidence, or pleadings, or both, or other parts of the charge, in order to ascertain whether the charges were erroneous and harmful, are too incomplete to be considered by this court when the grounds fail to set forth the evidence, pleading; or charge necessary to be considered, and fail, as an alternative, to designate the pages of the record where the necessary evidence, pleading or charge may be found. *Mutual Benefit Health &c. Assoc. of Omaha v. Hickman,*100 Ga. App. 348 (3) (111 S. E. 2d 380). Since the general grounds of the motion for a new trial have been abandoned, the judgment overruling the motion for a new trial must be affirmed.

*Judgment affirmed.*

*Bell and Hall, JJ., concur.*

*826*Parker, Clary & Kent, Hugh J. Martin, James Maddox,*for plaintiff in error.

*Fullbright & Duffey, Harl C. Duffey, Matthews, Maddox, Walton & Smith, John W. Maddox,*contra.